On April 27, 2016, the “2016 China Healthcare Industry Investment Summit†hosted by the Zero2IPO Group and the investment community was held at the Hyatt on the Bund. The annual outpatient volume of nearly 8 billion people in China has spawned a 3 trillion medical service market; as medical reforms are gradually involved in deep water, the health care market releases more dividends; mobile medical , medical services, biotechnology, precision medicine Countless areas have spawned numerous investment opportunities, and this market will grow to 6 trillion in 2020. In the dialogue session, Yu Zhengkun, founding managing partner of Jifeng Capital, Chen Qiao, managing partner of Haida Investment, Chen Yuxi, managing partner of Shande Capital, and Guo Yongchao, general manager of United Medical, and Liang Qi, founder of Ail Age Mr. Tang Delin, Chairman of New Vision, and Zhang Huali, Vice President and Partner of Xianyu Capital, discussed the “Medical Devices, How to Integrate All-roundâ€. The following is a wonderful sharing record: Yu Zhengkun, founding managing partner of Jifeng Capital: A series of national policies to encourage community medical benefits are medical devices I used to be IDG's medical partner. After ten years, I left IDG last year and founded Jifeng Capital. We raised RMB 1 billion and focused on medical projects. We have invested in 15 projects from last year to now. The company reported to the GEM, and the three companies reported the new three boards. We will finally share with you the hottest topic. Is the investor going to the New Third Board or going directly to the GEM? Now let's talk about the medical device industry. Individuals are very optimistic about this industry. What is special about it compared with drugs? First, compared with developed countries, medical devices are obviously more backward. China means backwardness and potential. Second, from the perspective of a series of national policies, it is necessary to encourage medical care and community clinics. Which aspect is it? In fact, the patients do not benefit. I look at the small clinics. I have to see them in the big hospitals. But in fact, it is beneficial to the medical device industry . Because the small clinics also need to equip the testing equipment, this is the topic of our discussion. , the topic of medical devices. Medical devices have recently issued a policy that has a big impact on everyone. It is a two-vote system. The state has introduced this. It is hoped that everyone will supply the products to the terminal at a relatively low price and reduce the profits of the suppliers. This will inevitably reduce the profit of the intermediate link. For enterprises, innovation and service are even more important. The State Council issued guidance on graded medical care last year. The State Council has a goal, and it is hoped that in 2017, 25% of outpatient visits will be completed at primary health care institutions. According to this speculation, it means that in 2017, the outpatient volume will be transferred from the current top three hospitals to the primary hospitals. There are more than 2,000 county-level hospitals in China, and the gap in equipment in these hospitals is about 30%. In the west, the gap reached 50% and the gap was huge. What makes us happy is that China actually has a group of good companies. They have good products. They are basically close to foreign-funded products and can also be exported. Even the domestic market has hurt the company like Medtronic and Johnson & Johnson. For example, there is an orthopedic company, listed on the New York Stock Exchange in 2010. It is an orthopaedic company in Medtronic, Changzhou. It was privatized by Medtronic from the main board of the NYSE for more than 800 million US dollars. gone. Because of the domestic market, it has hurt Medtronic, and there are many such companies.
Feline Infectious Peritonitis (FIP), referred to as Feline Infectious Peritonitis (FIP), is a fatal abnormal immune response that occurs in cats. It is caused by the mutation of the feline coronavirus carried by cats. As a high-incidence and fatal disease of pet cats, the current incidence of feline abdominal transmission is about 10%.
The symptoms of cats are usually divided into two categories, namely wet FIP and dry FIP, of which wet FIP accounts for the majority of all cases. About 70%, manifested as abdominal pleural effusion, abnormal bulging; dry FIP cats have different symptoms, depending on the type of organ affected by the virus.
So far, all feline feline feline treatments are based on the characteristics of the disease, and GS-441524 can play a role in the treatment of feline feline disease. Therefore, the therapeutic effect of GS-441524 is obviously more ideal, the dose used is less, the treatment cycle is shorter, and the efficacy, safety and convenience of operation are all good. Because of this, GS-441524 is considered by many pet owners and veterinarians to be a magic medicine that can effectively treat feline abdominal infection.
Gs 441524 Fip,Fip Treatment Gs441,Gs 441524 Fipv Cats,Gs 441524 For Fip XI AN RHINE BIOLOGICAL TECHNOLOGY CO.,LTD , https://www.rhinebiotech.com
